ProCE Banner Activity

Gestione del tumore endometriale avanzato o ricorrente con inibitori del checkpoint immunitario

Clinical Thought
Leggete le mie opinioni per scoprire come la gestione del tumore endometriale continua ad evolversi con l uso di immunoterapie come agenti singoli o in combinazioni.

Released: July 28, 2021

Expiration: July 27, 2022

No longer available for credit.

Share

Faculty

Maria-Pilar Barretina-Ginesta

Maria-Pilar Barretina-Ginesta, MD

Associate Professor
Medical Sciences Department
Girona University
Assistant Chief
Medical Oncology Department
Institut Catala D Oncologia
Girona, Spain

Supporters

Supported by an educational grant from

GlaxoSmithKline

Faculty Disclosure

Primary Author

Maria-Pilar Barretina-Ginesta, MD

Associate Professor
Medical Sciences Department
Girona University
Assistant Chief
Medical Oncology Department
Institut Catala D Oncologia
Girona, Spain

La dott.ssa Maria-Pilar Barretina-Ginesta, ha rivelato di aver ricevuto onorari per la consulenza da AstraZeneca, Clovis, GlaxoSmithKline, Merck Sharp & Dohme, Pharmamar e Roche; onorari per servizi non-CME/CE da AstraZeneca, Clovis, GlaxoSmithKline, Merck Sharp & Dohme, Pharmamar e Roche; e fondi per viaggi da AstraZeneca, Clovis, GlaxoSmithKline, Merck Sharp & Dohme, Pharmamar e Roche.